Russell Investments Group Ltd. lessened its position in FibroGen, Inc. (NASDAQ:FGEN – Get Rating) by 12.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 127,964 shares of the biopharmaceutical company's stock after selling 18,425 shares during the quarter. Russell Investments Group Ltd. owned 0.14% of FibroGen worth $1,537,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in FGEN. Allspring Global Investments Holdings LLC bought a new stake in shares of FibroGen in the 4th quarter worth about $530,000. DekaBank Deutsche Girozentrale increased its stake in FibroGen by 3.7% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 27,950 shares of the biopharmaceutical company's stock worth $397,000 after buying an additional 1,000 shares during the period. Virginia Retirement Systems ET AL purchased a new position in FibroGen in the 4th quarter worth about $141,000. Advisor Group Holdings Inc. increased its stake in FibroGen by 90.6% in the 4th quarter. Advisor Group Holdings Inc. now owns 8,909 shares of the biopharmaceutical company's stock worth $130,000 after buying an additional 4,236 shares during the period. Finally, Toronto Dominion Bank purchased a new position in FibroGen in the 4th quarter worth about $1,835,000. Institutional investors own 77.35% of the company's stock.
Get FibroGen alerts:FibroGen Stock Performance
NASDAQ FGEN opened at $14.33 on Thursday. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -6.05 and a beta of 0.87. The company's 50-day simple moving average is $11.99 and its two-hundred day simple moving average is $12.00. FibroGen, Inc. has a one year low of $7.81 and a one year high of $16.91.
FibroGen (NASDAQ:FGEN – Get Rating) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.94) by $0.16. FibroGen had a negative net margin of 83.64% and a negative return on equity of 100.51%. The firm had revenue of $29.81 million for the quarter, compared to the consensus estimate of $36.15 million. During the same quarter in the previous year, the firm earned ($1.45) EPS. The company's quarterly revenue was up 22.3% compared to the same quarter last year. Equities analysts expect that FibroGen, Inc. will post -3 earnings per share for the current fiscal year.Analyst Ratings Changes
Several research firms recently commented on FGEN. Cowen raised their price target on shares of FibroGen to $14.00 in a research note on Monday. The Goldman Sachs Group reduced their price target on shares of FibroGen from $9.00 to $8.00 and set a "sell" rating on the stock in a research note on Tuesday, May 24th. Finally, StockNews.com downgraded shares of FibroGen from a "buy" rating to a "hold" rating in a research report on Wednesday, August 10th.
About FibroGen
(Get Rating)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Articles
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- Which Semiconductor Stocks Are Ready For Big Price Moves?
- Miners Advance On Earnings Despite Broader Economic Challenges
- Lowe's Stands Out Amid Q2 Retail Reports
- Agilent Technologies Proves Its Worth VS Illumina
- Target's Results Cap Upside Potential For Retail Stocks
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.